Navigation Links
ImQuest Awarded SBIR Grant to Define the Mechanism of Action of Their Lead Anti-HIV Therapeutic Compound IQP-0410
Date:7/9/2008

FREDERICK, Md., July 9 /PRNewswire/ -- ImQuest Life Sciences announced today the successful acquisition of funding from the National Institutes of Health to define the mechanism of action of their dual-acting pyrimidinedione HIV inhibitor IQP-0410. The objective of this one-year Small Business Innovative Research (SBIR) award will allow ImQuest scientist to further understand how the pyrimidinediones inhibit the replication of HIV. IQP-0410 has been determined to primarily inhibit the function of the virion reverse transcriptase, but the clinical candidate also possesses a novel second mechanism of action which functions to prevent the entry of HIV into human target cells, extends the range of action of the compound to HIV-2 and results in enhanced levels of activity against multi-drug resistant virus strains. The SBIR award will allow ImQuest to better define the putative entry inhibition target, thus allowing the eventual development of an entirely new class of virus entry inhibitors. Dr. Robert W. Buckheit, Jr., Dr. Todd Parsley, and Ms. Tracy Hartman lead the research project.

"We are extremely pleased to receive this NIH SBIR award," said Dr. Buckheit. "IQP-0410 represents a completely novel dual-acting chemotype for development as an HIV therapeutic and ImQuest hopes to more completely understand how this compound inhibits HIV replication, initiate our planned clinical trials, and work on the development of a new generation of even more potent entry inhibitors that will provide HIV-infected individuals with yet another therapeutic option to fight their disease."

ImQuest plans to submit an IND to the Food and Drug Administration in the third quarter of 2008 in order to initiate Phase 1 human clinical trials with IQP-0410. Preclinical pharmacology and toxicology results have been highly encouraging that the compound will present a new highly potent and less toxic alternative for primary and salvage therapies in HIV-infected individuals. The pyrimidinedione series is being developed for use as both HIV therapeutics and topical microbicides.

ImQuest Life Sciences, a privately held U.S. company located in Frederick, Maryland specializes in early stage drug development of novel compounds for the treatment of infectious disease and cancer. ImQuest BioSciences, also located in Frederick, Maryland, is a leading provider of anti-infective therapeutic and microbicide development services to the biotechnology and pharmaceutical industry.

Robert W. Buckheit, Jr., Ph.D.

EVP, Chief Scientific Officer

rbuckheit@imquest.com


'/>"/>
SOURCE ImQuest Life Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. GeneNews CSO Dr. CC Liew awarded state honour by the Government of Malaysia
2. Mirus Bio Awarded Grants & Contracts of Over $5 Million
3. ICx Awarded $1.5 M Contract by Department of Homeland Security for Development of Next Generation Bio Aerosol Systems
4. ViPS Awarded Enterprise Systems Development (ESD) Contract By CMS
5. GlaxoSmithKline Awarded U.S. Department of Defense Contract to Pursue Novel Antibacterial Research Program
6. Isis Announces $4.2 Million in Government Contracts Awarded to Its Ibis Subsidiary for Biodefense Applications Development
7. Foundation for Biomedical Research Board Chairman Awarded Congressional Gold Medal
8. Isis Awarded $1.5 Million NIH Grant to Improve Chemical Properties of RNAi-Based Therapeutics
9. Caliper Life Sciences Awarded National Institute of Environmental Health Services Contract Valued to $7.0 Million
10. Implicit Awarded US $16.3 Million U.S. Government Contract to Develop Immunomodulatory Drug for Biodefense Threats
11. BIO-key(R) Awarded Contract to Deploy Incident Reporting System for Littleton, CO Police Department
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... -- According to a new market research report "Oligonucleotide ... Equipment), Application (Research, PCR, Gene, DNA, NGS, Diagnostic, RNAI), End user ... global market is expected to reach USD 2.20 Billion by 2021 ... during the forecast period. Continue Reading ... ...
(Date:12/8/2016)... 2016  OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ... cancer immunotherapies, today announced financial results for the ... are delivering on our commitment to address an ... We are pleased with the early clinical response ... we are focused on advancing our lead program ...
(Date:12/8/2016)... , Dec. 8, 2016  Renova™ Therapeutics, ... congestive heart failure and type 2 diabetes, announced ... a novel adeno-associated virus (AAV) vector developed in ... M.D., Ph.D., at Stanford University. The company plans ... paracrine gene therapy product pipeline. ...
(Date:12/8/2016)... OXFORD, England , December 8, 2016 /PRNewswire/ ... (OGT), das Unternehmen für Molekulargenetik, erweitert seine Palette ... SureSeq myPanel™ NGS Custom FH Panels, das ein ... Hypercholesterinämie (FH) ermöglicht. Das Panel bietet eine Erkennung ... Number Variations (CNV) mit einem einzigen kleinen Panel ...
Breaking Biology Technology:
(Date:6/22/2016)... , June 22, 2016   ... management and verification solutions, has partnered with ... software solutions for Visitor Management, Self-Service Kiosks ... provides products that add functional enhancements to ... provides corporations and venues with an automated ...
(Date:6/21/2016)... 21, 2016 NuData Security announced today that ... of principal product architect and that Jon ... customer development. Both will report directly to ... moves reflect NuData,s strategic growth in its product ... customer demand and customer focus values. ...
(Date:6/16/2016)... The global Biometric ... USD 1.83 billion by 2024, according to a ... proliferation and increasing demand in commercial buildings, consumer ... the market growth.      (Logo: ... of advanced multimodal techniques for biometric authentication and ...
Breaking Biology News(10 mins):